title: Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.
abstract: Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m(2) and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.
authors.affiliation: University of Utah Health Science Center, Salt Lake City, Utah, USA. wolfram.samlowski@hci.utah.edu
authors.forename: Wolfram E
authors.initials: WE
authors.lastname: Samlowski
authors.forename: James
authors.initials: J
authors.lastname: Moon
authors.forename: J Philip
authors.initials: JP
authors.lastname: Kuebler
authors.forename: Craig R
authors.initials: CR
authors.lastname: Nichols
authors.forename: David R
authors.initials: DR
authors.lastname: Gandara
authors.forename: Howard
authors.initials: H
authors.lastname: Ozer
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Williamson
authors.forename: James N
authors.initials: JN
authors.lastname: Atkins
authors.forename: David E
authors.initials: DE
authors.lastname: Schuller
authors.forename: John F
authors.initials: JF
authors.lastname: Ensley
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D012008:Recurrence; D012720:Severity of Illness Index; D043823:Taxoids / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin